Loading...
Loading...
- Theratechnologies Inc THTX reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.
- Trogarzo sales declined 8% to $6.63 million on lower unit sales as patients refrained from visiting their physicians. Competitive pressures and higher rebates also impacted the sales.
- It posted a net loss of $(0.10) for the quarter compared to $(0.09) a year ago, missing the consensus loss of $(0.07).
- The Company used $(3.13) million in operating cash flow.
- Price Action: THTX shares closed lower by 0.14% at $3.50 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in